Hepatocellular Carcinoma

A diagnostic marker in hepatocellular carcinoma

A research team from South Korea investigated the expression profile of E2F5 in primary hepatocellular carcinomas (HCCs) and explored the biological implications of E2F5 overexpression. They found that E2F5 is commonly overexpressed ...

Jan 31, 2011
popularity0 comments 0

A new role of glypican-3 in hepatocellular carcinoma

A study group from Japan analyzed the association of glypican-3 (GPC3) expression with Wnt and other growth signaling molecules in hepatocellular carcinoma (HCC). They found altered expressions of various matrix metalloproteinases ...

Aug 02, 2010
popularity0 comments 0

Lapatinib shows minimal effect against liver cancer

Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results ...

Sep 08, 2009
popularity0 comments 1

New DNA testing for liver cancer could improve survival

Detection of small fragments of tumor DNA, known as circulating tumor DNA, in a patient's pre-surgery serum samples predicts early recurrence of hepatocellular carcinoma and may guide treatment, according to a study published ...

Sep 10, 2015
popularity7 comments 0

Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitide infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).

Compared to other cancers, HCC is quite a rare tumor in the United States. In countries where hepatitis is not endemic, most malignant cancers in the liver are not primary HCC but metastasis (spread) of cancer from elsewhere in the body, e.g., the colon. Treatment options of HCC and prognosis are dependent on many factors but especially on tumor size and staging. Tumor grade is also important. High-grade tumors will have a poor prognosis, while low-grade tumors may go unnoticed for many years, as is the case in many other organs, such as the breast, where a ductal carcinoma in situ (or a lobular carcinoma in situ) may be present without any clinical signs and without correlate on routine imaging tests, although in some occasions it may be detected on more specialized imaging studies like MR mammography.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News